ArticleBMC pharmacology & toxicology2025
Apocynin ameliorates liver fibrosis events in vivo through modulation of oxidative stress, inflammatory, and apoptotic mediators.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redox Imbalance in the Cardiohepatic Syndrome: The Emerging Role of Oxidative Stress in Cirrhosis-Associated Cardiac Dysfunction.Antioxidants (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver has a tremendous regeneration potential, yet chronic liver injury poses a life-threatening condition if not managed appropriately. Apocynin, an NADPH oxidase inhibitor, has been a central focus of attention in recent years due to its significant antioxidant/anti-inflammatory potentials. In this study, we evaluated the acute toxicity and hepatoprotective effects of Apocynin against thioacetamide (TAA)-induced liver fibrosis in rats. Liver fibrosis was induced by 200 mg/kg TAA three times/week for two months, along with treatment with distilled water (positive control), silymarin (reference, 50 mg/kg), or apocynin (50 and 100 mg/kg/day). Hepatic tissues were screened for histopathological, biochemical, and immunohistochemical changes, while hepatic homogenate was examined for the antioxidant contents (catalase, CAT; superoxide dismutase, SOD) and MDA levels. Apocynin treatment showed significant hepatoprotective effects against TAA-hepatotoxicity, evidenced by reduced hepatic tissue alterations with a slight fibroplasia, reduction of hepatomegaly, less hepatic nodules/necrosis, and recovered hepatic function. Additionally, apocynin administration reduced oxidative stress by lowering pro-oxidants (MDA) and up-regulating antioxidants (SOD and CAT). Furthermore, the anti-apoptotic and anti-fibrotic effects of apocynin were confirmed by reduced pro-apoptotic P53 proteins and β-catenin (tissue proliferation/aggregation enhancer). Apocynin treatment ameliorated ECM generation (lowered collagen bundles/fibrous septa) and reduced inflammatory (less TNf-α and IL-6 cytokines) mediators, all of which restored liver functional parameters (ALT, AST, ALP, and albumin). Apocynin attenuated TAA-mediated liver fibrosis by its modulatory potentials on several cytoprotective mechanisms associated with the oxidative stress/inflammation, making it a viable therapeutic source for liver fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.